182 related articles for article (PubMed ID: 36302501)
1. What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure-Activity Relationships.
Thomas R; Tennant RE; Oliveira AAF; Ponting DJ
Chem Res Toxicol; 2022 Nov; 35(11):1997-2013. PubMed ID: 36302501
[TBL] [Abstract][Full Text] [Related]
2. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
3. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
4. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of
Chakravarti S
Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457
[TBL] [Abstract][Full Text] [Related]
5. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
6. Developing Structure-Activity Relationships for
Cross KP; Ponting DJ
Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
[TBL] [Abstract][Full Text] [Related]
7. Quantitative structure carcinogenicity relationship for detecting structural alerts in nitroso-compounds.
Helguera AM; González MP; D S Cordeiro MN; Pérez MA
Toxicol Appl Pharmacol; 2007 Jun; 221(2):189-202. PubMed ID: 17477948
[TBL] [Abstract][Full Text] [Related]
8. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
Dos Santos CEM; Dorta DJ; de Oliveira DP
Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
[TBL] [Abstract][Full Text] [Related]
9. International Commission for Protection Against Environmental Mutagens and Carcinogens. Application of SAR methods to non-congeneric data bases associated with carcinogenicity and mutagenicity: issues and approaches.
Richard AM
Mutat Res; 1994 Feb; 305(1):73-97. PubMed ID: 7508549
[TBL] [Abstract][Full Text] [Related]
10. Comparison of criteria used to access carcinogenicity in CPANN QSAR models versus the knowledge-based expert system Toxtree.
Fjodorova N; Novič M
SAR QSAR Environ Res; 2014; 25(6):423-41. PubMed ID: 24716754
[TBL] [Abstract][Full Text] [Related]
11. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
[TBL] [Abstract][Full Text] [Related]
12. Quantitative structure-carcinogenicity relationship for detecting structural alerts in nitroso compounds: species, rat; sex, female; route of administration, gavage.
Morales Helguera A; Pérez González M; Dias Soeiro Cordeiro MN; Cabrera Pérez MA
Chem Res Toxicol; 2008 Mar; 21(3):633-42. PubMed ID: 18293904
[TBL] [Abstract][Full Text] [Related]
13. Mutagenic impurities in pharmaceuticals: a critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2013 Nov; 67(2):299-316. PubMed ID: 23988886
[TBL] [Abstract][Full Text] [Related]
14. Quantitative structure-activity relationship modelling of the carcinogenic risk of nitroso compounds using regression analysis and the TOPS-MODE approach.
Helguera AM; Pérez-Machado G; Cordeiro MN; Combes RD
SAR QSAR Environ Res; 2010 Apr; 21(3-4):277-304. PubMed ID: 20544552
[TBL] [Abstract][Full Text] [Related]
15. Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potency.
Venkatapathy R; Wang CY; Bruce RM; Moudgal C
Toxicol Appl Pharmacol; 2009 Jan; 234(2):209-21. PubMed ID: 18977375
[TBL] [Abstract][Full Text] [Related]
16. Nitrosamine carcinogenicity: a quantitative Hansch-Taft structure-activity relationship.
Wishnok JS; Archer MC; Edelman AS; Rand WM
Chem Biol Interact; 1978 Jan; 20(1):43-54. PubMed ID: 630644
[TBL] [Abstract][Full Text] [Related]
17. Liver specificity of the carcinogenicity of NOCs: a chemical-molecular perspective.
Yuan J; Pu Y; Yin L
Chem Res Toxicol; 2012 Nov; 25(11):2432-42. PubMed ID: 23043541
[TBL] [Abstract][Full Text] [Related]
18. [Quantitative structure-activity relationship prediction of carcinogenicity of N-nitroso compounds based on category approach and read-across].
Liang QQ; Zheng WW; He GS; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):621-627. PubMed ID: 28693087
[No Abstract] [Full Text] [Related]
19. Absolute Quantitation of
Wang Q; Liu Z; Liu Y; Chen H
J Am Soc Mass Spectrom; 2022 May; 33(5):875-884. PubMed ID: 35446584
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous Estimation of Six Nitrosamine Impurities in Valsartan Using Liquid Chromatographic Method.
Bodiwala KB; Panchal BG; Savale SS; Dave JB; Sureja DK; Dhameliya TM; Chhabria MT
J AOAC Int; 2022 Feb; 105(1):1-10. PubMed ID: 34338773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
